home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 05/20/24

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

2024-05-20 13:02:41 ET Summary Cellectar Biosciences, Inc. is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. The company has positive topline data from a pivotal study, with a high response rate in patients with Wal...
CLRB - Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

2024-05-14 13:05:17 ET Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Conference Call May 14, 2024, 08:30 AM ET Company Participants James Caruso - President and Chief Executive Officer Andrei Shustov - Senior Vice President, Medical Jarrod Longcor - Chief O...

CLRB - Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18

2024-05-14 06:44:49 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...

CLRB - Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...
CLRB - Cellectar Biosciences Q1 2024 Earnings Preview

2024-05-13 13:37:31 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...

CLRB - Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating ...

CLRB - Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its fina...
CLRB - Radiopharma stocks higher as sector welcomes the latest M&A deal

2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...

CLRB - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

CLRB - Outperform Recommendation Issued On CLRB By Oppenheimer

2024-03-28 09:15:05 ET Oppenheimer analyst issues OUTPERFORM recommendation for CLRB on March 28, 2024 07:33AM ET. The previous analyst recommendation was Outperform. CLRB was trading at $3.635 at issue of the analyst recommendation. Historical Analyst Recommendations ...
Previous 10 Next 10